These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2813190)

  • 1. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker".
    Abrahamsson PA; Falkmer S; Fält K; Grimelius L
    Pathol Res Pract; 1989 Sep; 185(3):373-80. PubMed ID: 2813190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
    Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
    Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin.
    Xing N; Qian J; Bostwick D; Bergstralh E; Young CY
    Prostate; 2001 Jun; 48(1):7-15. PubMed ID: 11391682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.
    Fixemer T; Remberger K; Bonkhoff H
    Prostate; 2002 Oct; 53(2):118-23. PubMed ID: 12242726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate.
    Van de Voorde WM; Van Poppel HP; Verbeken EK; Oyen RH; Baert LV; Lauweryns JM
    Mod Pathol; 1995 Aug; 8(6):591-8. PubMed ID: 8532689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between histopathological form and the degree of neuroendocrine differentiations in prostate cancer.
    Bocan EV; Mederle O; Sârb S; Minciu R; Agapie D; Raica M
    Rom J Morphol Embryol; 2011; 52(4):1215-8. PubMed ID: 22203925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
    Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
    Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
    Bohrer MH; Schmoll J
    Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
    Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
    Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent neuroendocrine differentiation in prostatic carcinoma.
    di Sant' Agnese PA
    Semin Diagn Pathol; 2000 May; 17(2):149-61. PubMed ID: 10839615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine cells in pancreatic duct adenocarcinoma: an immunohistochemical study.
    Linder S; Myrvold K; Falkmer UG; Qvigstad G; Waldum HL; Falkmer SE
    J Exp Clin Cancer Res; 2006 Jun; 25(2):213-21. PubMed ID: 16918133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma.
    Aprikian AG; Cordon-Cardo C; Fair WR; Reuter VE
    Cancer; 1993 Jun; 71(12):3952-65. PubMed ID: 7685237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptors for BPH growth factors are located in some neuroendocrine cells.
    Iwamura M; Koshiba K; Cockett AT
    Prostate Suppl; 1998; 8():14-7. PubMed ID: 9690658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroendocrine differentiation in the progression of prostate cancer.
    Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
    Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
    Cohen RJ; Glezerson G; Haffejee Z
    Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.